VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PAHCPhibro Animal Health Corporation
$31.69$1.3B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPAHCCash Flow

Phibro Animal Health Corporation (PAHC) Cash Flow Statement

22Y historyFree accessUpdated daily

Cash generation remains challenged by working capital volatility, evidenced by a $26.7M outflow in 2026Q3 and a negligible free cash flow margin of 0.2%.

PAHC Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMJun'25Jun'24Jun'23Jun'22Jun'21Jun'20Jun'19Jun'18Jun'17Jun'16Jun'15Jun'14Jun'13Jun'12Jun'07Jun'06Jun'05Jun'04Jun'03Jun'02Jun'01Jun'00
Cash from Operations66.13M80.12M87.59M13.31M31.65M48.31M59.35M47.17M70.01M98.4M37.22M68.7M-712K415K31.99M-4.73M810K-6.16M2.86M34.66M-4.75M13.14M-7.91M
Operating CF Margin %-6.18%8.61%1.36%3.36%5.8%7.42%5.7%8.54%12.87%4.95%9.18%-0.1%0.06%4.89%-1.04%0.2%-1.69%0.81%10.26%-1.45%4.11%-2.45%
Operating CF Growth %415.2%-8.53%558.11%-57.95%-34.48%-18.61%25.82%-32.62%-28.85%164.39%-45.83%9749.44%-271.57%-98.7%776.28%-683.95%113.15%-315.38%-91.75%829.68%-136.15%266.12%-
Net Income95.23M48.26M2.42M32.61M49.17M54.38M33.55M54.71M64.88M64.61M82.73M60.28M-3.13M24.89M6.98M-6.7M-13.1M-22.1M12.9M-17.6M-51.8M-14.9M10.1M
Depreciation & Amortization50.58M45.6M36.18M34.01M32.7M31.89M32.34M27.56M26.94M26M23.45M21.6M21.45M19.02M17.53M10.72M13.99M18.11M10.66M10.99M12.36M10.41M11.87M
Stock-Based Compensation952K717K475K001.13M2.26M2.26M334K00073K215K000000000
Deferred Taxes18.03M-4.88M-7.84M-2.84M-806K-2.18M8.13M-105K6.39M-28K-22.24M4.76M1.29M-12.04M-2.39M1.2M-520K-1.02M330K6.46M11.24M-5.73M1.44M
Other Non-Cash Items925K11.98M23.25M-9.34M-4.79M-7.04M-3.27M-1.32M6.31M127.7M7.07M2.39M910K488K1.26M-6.75M-23.96M-46.45M20.37M58.31M29.35M-56.54M-15.34M
Working Capital Changes-99.59M-21.56M33.11M-41.13M-44.64M-29.87M-13.66M-35.94M-33.88M1.4M-46.06M-16.95M-28.23M-34.84M5.2M-3.2M24.4M45.3M-41.4M-23.5M-5.9M79.9M-15.98M
Change in Receivables-17.03M-55.21M-8.68M5.33M-23.63M-18.21M28.71M-23.68M-11.9M-2.77M-13.09M-1.88M-14.68M-729K-3.77M-17.6M-1.6M4.4M-4.5M5.3M19.9M1.5M0
Change in Inventory-98.7M-44.29M2.64M-11.22M-47M-12.5M-12.93M-20.98M-24.29M5.43M-16.44M-19.35M-3.19M-25.11M-745K7.4M-200K-18M9.2M-2.4M-1.6M-33.4M0
Change in Payables-4.2M45.55M12M-22.83M26.36M3.18M-7.67M12.09M2.45M-3.12M-3.25M4.8M1.68M-6.6M6.41M-4.4M-5.3M10.5M8.6M-17.2M13.1M-18.7M0
Cash from Investing-62.04M-288.69M-48.19M-74.02M-22.58M-18.58M-120.39M-14.13M-84.61M-21.9M-82.79M-34.46M-19.41M-37.34M-17.74M-11.93M-5.3M20K9.07M-3.97M-17.36M-40.15M-4.06M
Capital Expenditures-53.36M-38.29M-41.24M-51.79M-37.04M-29.32M0-29.89M-18.55M-20.9M-36.35M-20.06M-19.85M-19.95M-14.82M-10.62M-15.09M-7.49M-6.13M-8.51M-8.52M-6.61M-22.6M
CapEx % of Revenue3.56%2.95%4.05%5.3%3.93%3.52%4.25%3.61%2.26%2.73%4.84%2.68%2.87%3.05%2.27%2.34%3.79%2.06%1.73%2.52%2.59%2.07%7%
Acquisitions5.35M-286.53M-3.28M0-13.51M29.32M-54.55M-9.84M-15M0-46.58M-10.38M0-18.69M-3.38M00000000
Investments-----------------------
Other Investing-1.5M1.13M326K776K620K-30.58M-34.84M-404K-1.06M-1M137K-4.03M434K1.3M465K-1.31M9.79M7.51M15.2M4.54M-8.84M-33.54M18.54M
Cash from Financing-12.71M207.13M-6.77M26.99M16.34M-17M40.94M-4.11M-11.78M-53.74M50.38M-15.35M4.78M10.88M-8.22M19.86M-540K14.25M-17.78M-26.38M13.68M39.9M11.35M
Debt Issued (Net)-229.24M235.99M12.71M42.69M40.63M5.38M60.35M13.35M-1.4M-39.53M62.07M-1.09M-80.1M14.8M-8.22M00000000
Equity Issued (Net)00000001.13M5.7M5.54M4.02M1.33M114.43M0000000000
Dividends Paid-19.46M-19.45M-19.44M-19.44M-19.44M-19.43M-19.42M-18.59M-16.07M-15.83M-15.71M-15.6M-25M-3M000000000
Share Repurchases000000000000000-580K0-26.4M00045M0
Other Financing235.98M-9.4M-31K3.74M-4.84M-2.94M000-3.92M00-4.55M-924K019.86M-540K14.25M-17.78M-26.38M13.68M39.9M11.35M
Net Change in Cash-5.42M-2.57M29.33M-32.97M24.04M13.87M-21.23M28.41M-26.91M22.48M4.39M17.39M-15.55M-26.53M5.3M3.31M-4.91M8.03M-5.61M4.76M-8.43M12.44M-620K
Free Cash Flow12.77M41.83M46.36M-38.48M-5.39M18.99M25.3M17.28M51.46M77.5M866K48.65M-20.56M-19.53M17.16M-15.35M-14.28M-13.65M-3.27M26.15M-13.27M6.53M-30.51M
FCF Margin %0.85%3.23%4.56%-3.94%-0.57%2.28%3.16%2.09%6.28%10.14%0.12%6.5%-2.97%-2.99%2.62%-3.39%-3.58%-3.75%-0.92%7.74%-4.04%2.04%-9.45%
FCF Growth %-73.97%-9.76%220.46%-613.33%-128.42%-24.97%46.45%-66.42%-33.6%8849.19%-98.22%336.63%-5.25%-213.8%211.82%-7.49%-4.62%-317.43%-112.5%297.06%-303.22%121.4%-
FCF per Share0.311.031.14-0.95-0.130.470.620.431.271.940.021.22-0.64-0.640.56-0.40-0.24-0.23-0.050.44-0.220.11-0.51
FCF Conversion (FCF/Net Income)0.13x1.66x36.26x0.41x0.64x0.89x1.77x0.86x1.08x1.52x0.45x1.14x0.23x0.02x4.59x0.71x-0.06x0.28x0.22x-1.97x0.09x-0.88x-0.78x
Interest Paid032.07M17.25M14.57M11.16M10.81M11.58M12.25M11.21M14.6M14.21M12.91M45.37M33.82M34.06M00000000
Taxes Paid013.4M15.43M20.41M17.85M19.39M20.87M16.21M15.19M14.76M16.83M10.78M12.21M7.06M7.22M00000000

Key Metrics

Growth RegimeExpanding
ProfitabilityModerate
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Working Capital Volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Earnings Quality Lacks Cash Conversion

As reported in recent financial filings, PAHC's operating cash flow to net income ratio has fluctuated significantly, dropping to 0.67 in 2026Q3, which suggests that reported accounting profits are not consistently translating into actual cash generation due to persistent accrual-based adjustments and operational timing differences.

The wide variance in the OCF/NI ratio indicates that earnings quality remains inconsistent, often decoupled from the underlying cash reality of the business. Investors should monitor whether this divergence stems from structural inefficiencies in revenue recognition or simply the timing of large-scale integrator payments.

Free Cash Flow Margin Compression

Based on the provided cash flow data, FCF margins have struggled to maintain positive territory, reaching a negligible 0.2% in 2026Q3, which highlights the difficulty in sustaining cash generation amidst rising capital requirements and the ongoing integration of new product portfolios into the core business.

The inability to consistently generate meaningful free cash flow suggests that the company's current growth phase is highly capital-intensive. This trend warrants further investigation into whether the recent acquisition of Zoetis assets will eventually provide the scale necessary to improve these thin margins.

Working Capital Dragging Cash Flow

According to the latest quarterly statements, PAHC experienced a significant working capital outflow of $26.7M in 2026Q3, a recurring trend that appears to be the primary factor suppressing operating cash flow and limiting the company's ability to fund internal growth through organic cash generation.

The frequent negative swings in working capital suggest that the company may be carrying excessive inventory or facing extended collection cycles from its integrator customer base. This pattern implies that the business model is inherently sensitive to the liquidity constraints of its agricultural partners.

Capital Intensity Constraining Cash Flow

As indicated by the historical data, PAHC has maintained a consistent capital expenditure profile, with CapEx/Revenue ratios averaging near 3.5% over the last ten quarters, reflecting the ongoing necessity of maintaining specialized manufacturing infrastructure to support its complex medicated feed additive and vaccine production lines.

The steady level of capital reinvestment suggests that the company is prioritizing the maintenance and potential expansion of its physical footprint over immediate cash return. This capital intensity appears to be a structural requirement of the industry, limiting the flexibility of free cash flow during periods of revenue volatility.

PAHC — Frequently Asked Questions

Quick answers to the most common questions about buying PAHC stock.

How much cash does Phibro Animal Health Corporation (PAHC) generate from operations?

Phibro Animal Health Corporation (PAHC) generated $80.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Phibro Animal Health Corporation's free cash flow?

Phibro Animal Health Corporation (PAHC) generated $41.8M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Phibro Animal Health Corporation's capital expenditure (CapEx)?

Phibro Animal Health Corporation (PAHC) spent $38.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Phibro Animal Health Corporation distribute cash to shareholders?

In 2025, Phibro Animal Health Corporation (PAHC) returned $19.4M to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.